Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Product Name : MK-0616
Product Type : Peptide
Upfront Cash : Inapplicable
August 25, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Product Name : MK-0616
Product Type : Peptide
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Product Name : MK-0616
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable